SEC Tracker
Get the app
KROS · XBRL financial data

Keros Therapeutics financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (KROS's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Revenue——0000*211,19218,16814,124380*320
Revenue from contracts with customers8143*8337388year only211,24618,16814,262385*3670
Research and development34,14037,493*38,25840,51549,22545,631*48,70943,50319,51917,912*16,09722,331
General and administrative9,1489,105*10,3089,9619,82010,665*10,49714,48210,12711,743*10,1478,606
Total operating expenses43,28846,598*48,56650,47659,04556,296*59,20657,98529,64629,655*26,24430,937
Operating income (loss)(43,280)(46,455)*(48,483)(50,439)(58,657)(53,254)*152,040(39,817)(15,384)(29,270)*(25,877)(30,937)
Interest expense00*———year only——————
Other income (expense)3,840(10,943)*(437)(196)(92)(229)*(338)(221)(253)273*(166)(60)
Income tax expense (benefit)—year only000300*10,043(2,222)(1,424)(1,514)*00
Net income (loss)(39,440)(40,243)*(43,114)(45,257)(52,956)(46,026)*148,451(30,696)(7,280)(23,461)*(23,708)(28,710)
Earnings per share, basic USD per share(1.33)(1.34)*(1.21)(1.25)(1.41)(1.14)*3.66(0.76)(0.18)—(1.21)(1.45)
Earnings per share, diluted USD per share(1.33)(1.34)*(1.21)(1.25)(1.41)(1.14)*3.62(0.76)(0.18)—(1.21)(1.45)
Weighted average shares, basic thousands of shares29,66830,127*35,68536,10337,59140,338*40,55940,61340,623—19,63019,800
Weighted average shares, diluted thousands of shares29,66830,127*35,68536,10337,59140,338*41,02140,61340,623—19,63019,800

Balance sheet

CSV

Fiscal quarters (KROS's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Cash and cash equivalents287,893331,147442,443405,863530,684559,931720,541690,215693,472287,415281,497257,606
Accounts receivable—14322643882,74217,29115,8163,4923,5674000
Prepaid and other current assets16,54216,00320,45726,84720,97426,22021,67726,77722,34322,2026,5307,027
Total current assets304,435347,293463,126432,714552,046588,893759,509732,808719,307315,434290,677266,883
Property and equipment, net3,3574,1344,4344,2924,3664,2374,4734,8364,5644,2973,9623,715
Right-of-use asset15,66915,33414,99514,64919,82319,25118,66718,07217,46316,84116,20515,553
Total assets326,247370,025485,819455,022579,271615,886784,561757,165742,783338,021312,293287,600
Accounts payable3,8675,4504,9866,5354,9814,6026,6365,2672,2981,9671,4931,816
Accrued liabilities12,22317,91812,68213,61422,16920,87017,29019,96415,17416,0398,8597,740
Total current liabilities16,70124,37318,71821,24529,00727,45039,37934,70724,09220,41412,85312,153
Lease liability, non-current13,70413,43913,15412,86117,42916,88316,31115,72415,11114,47513,81013,127
Total liabilities30,40537,81231,87234,10646,43644,33355,69050,43139,20334,88926,66325,280
Accumulated deficit(341,183)(381,426)(424,540)(469,797)(522,753)(568,779)(420,328)(451,024)(458,304)(481,765)(505,473)(534,183)
Total stockholders' equity295,842332,213453,947420,916532,835571,553728,871706,734703,580303,132285,630262,320
Total liabilities and equity326,247370,025485,819455,022579,271615,886784,561757,165742,783338,021312,293287,600
Common shares outstanding (cover page) thousands of shares29,95935,98336,08437,52240,50740,56240,61540,61530,46619,71819,79219,827

Cash flows

CSV

Fiscal quarters (KROS's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Net income (loss)(39,440)(40,243)*(43,114)(45,257)(52,956)(46,026)*148,451(30,696)(7,280)(23,461)*(23,708)(28,710)
Stock-based compensation8,711*7,324*8,0708,785*8,817*9,200*8,8638,542*3,986*7,305*6,1995,377*
Net cash from operating activities(33,982)*(25,459)*(44,560)(39,801)*(30,500)*(46,008)*161,171(29,623)*3,249*(27,292)*(3,529)(20,421)*
Purchases of property and equipment550*541*946310*386*289*565720*132*134*73155*
Net cash from investing activities(550)*(541)*(946)(310)*(386)*(289)*(565)(720)*(132)*(134)*(73)(155)*
Proceeds from issuing common stock0*—151,340—————————
Share repurchases—————year only———year only——
Net cash from financing activities284*69,254*156,8023,531*155,944*75,544*417*140*(378,631)*(2,316)(3,315)*
Net change in cash(34,248)*43,254*111,296(36,580)*125,058*29,247*160,610(30,326)*3,257*(406,057)*(5,918)(23,891)*

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($K)Revenue, quarter ($K)Operating cash flow, quarter ($K)Shares outstandingRunwayQuarter
Keros Therapeutics257,6060(20,421)*19.8M12.6 quarters 10-QJun 30, 2026
Zevra Therapeutics122,14837,75610,047*59.5M— 10-QSep 30, 2026
Theravance Biopharma219,76620,731(6,965)*51.9M55.7 quarters 10-QJun 30, 2026
aTYR PHARMA16,160not reported(9,351)*98.1M6.1 quarters 10-QJun 30, 2026
Arvinas88,000500(10,400)*65.5M13.0 quarters 10-QSep 30, 2026
Arbutus Biopharma19,1711,014(6,018)*197.8M15.4 quarters 10-QJun 30, 2026
CytoDyn16,359not reported(7,726)1.5B2.1 quarters 10-QAug 31, 2026
Myriad Genetics115,200190,700(8,300)*95.6M13.9 quarters 10-QJun 30, 2026
Kura Oncology70,24220,874(62,549)*89.0M8.3 quarters 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.